Exchange: NASDAQ·Updated 03:59 PM EDT

EDOC News

News
all
press releases
In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.  
Stocktwits
This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.
Stocktwits
Multiple brokerages cut their price target on the stock after Doximity reported a fall in third-quarter earnings and a soft fourth-quarter revenue outlook.
Stocktwits
Following the ouster of CEO Jason Gorevic last year, the telehealth company has been trying to chart a recovery path.
Stocktwits

Advertisement|Remove ads.